
Pasithea Therapeutics Corp.
93
Recent developments include FDA orphan drug designation for PAS-004 in ALS, appointment of a new Chief Medical Officer, FDA rare pediatric disease status for NF1, a $60 million equity offering, and promising clinical trial results showing tumor shrinkage and pathway inhibition.
- PAS-004 received FDA orphan drug designation for ALS, supporting its development in this indication [N1].
- Kartik Krishnan was appointed as Chief Medical Officer to advance clinical development [N2].
- PAS-004 won FDA rare pediatric disease status for treating neurofibromatosis type 1, potentially facilitating regulatory pathways [N3].
- Pasithea completed a $60 million public offering to advance PAS-004 and its broader pipeline [N5].
- Interim Phase 1 trial results showed tumor shrinkage in neurofibromatosis patients and up to 91% pERK inhibition in advanced cancer patients [N7][N1].
- HC Wainwright & Co. initiated coverage with a buy recommendation, reflecting positive market interest [N4].
- Dr. James Lee was appointed to the Scientific Advisory Board to support PAS-004 development for inflammatory diseases [N6].
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company developing innovative therapies targeting the MAPK pathway, focusing on RASopathies such as neurofibromatosis type 1 (NF1), MAPK pathway-driven tumors, ALS, and inflammatory diseases. Its lead candidate, PAS-004, is a macrocyclic MEK 1/2 inhibitor designed to improve upon existing MEK inhibitors by offering better selectivity, oral bioavailability, metabolic stability, and a more favorable safety profile. PAS-004 is currently in Phase 1 clinical trials for advanced cancers and NF1-associated plexiform neurofibromas, with plans for further regulatory studies and expanded indications. The company also has an early-stage discovery program targeting schizophrenia. Pasithea has received multiple FDA designations for PAS-004 and maintains strong liquidity to support ongoing development.
Pasithea Therapeutics Corp. is a clinical-stage biotech focused on developing PAS-004, a macrocyclic MEK inhibitor targeting RASopathies including NF1, MAPK pathway-driven tumors, ALS, and inflammatory diseases. PAS-004 is in multiple clinical trials including Phase 1 advanced cancer and Phase 1/1b NF1-PN studies, with favorable safety and pharmacokinetic profiles reported. The company holds FDA orphan drug and rare pediatric disease designations for PAS-004. Financially, as of September 30, 2026, Pasithea reported a net loss of $6.58 million and maintains strong liquidity with $41.2 million cash and a current ratio of 15.67. Recent developments include key executive appointments, a $60 million equity raise, and promising clinical data showing tumor shrinkage and pathway inhibition [S2][N1][N2][N5][N7]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Pasithea's PAS-004 shows promising clinical safety and pharmacokinetic profiles with preliminary efficacy signals in advanced cancer and NF1 patients. The macrocyclic design may offer advantages over existing MEK inhibitors, potentially improving patient tolerability and dosing convenience. FDA orphan drug and rare pediatric disease designations support regulatory incentives. The company has secured substantial funding through equity offerings and maintains strong liquidity to advance clinical programs. Expansion into multiple indications including ALS and inflammatory diseases, supported by investigator-initiated trials and collaborations, could broaden PAS-004's utility. Recent executive appointments and scientific advisory board additions strengthen development capabilities.
Pasithea remains a clinical-stage company with no approved products, facing typical biotech risks including clinical trial failures, regulatory hurdles, and uncertain commercial viability. The safety and efficacy advantages of PAS-004 over existing MEK inhibitors remain to be conclusively demonstrated in registrational trials. The company reports ongoing net losses and depends on continued financing to fund operations. Competitive pressures from other MEK inhibitors and alternative therapies exist. Delays or negative outcomes in clinical trials or regulatory reviews could adversely impact development progress and valuation. The broad indication strategy may dilute focus and resources.
Pasithea's moat is centered on its proprietary macrocyclic MEK inhibitor PAS-004, which is designed to address limitations of existing MEK inhibitors such as toxicity, dosing frequency, and pharmacokinetic variability. The macrocyclic structure potentially offers improved selectivity, metabolic stability, and a broader therapeutic window. The company has secured orphan drug and rare pediatric disease designations from the FDA, which may provide regulatory and market advantages. Its clinical-stage pipeline with ongoing trials and a focus on multiple indications including rare diseases and cancers adds to its competitive positioning. However, as a clinical-stage biotech, the moat is contingent on successful clinical development and regulatory approvals.
• Clinical Development Risk: PAS-004 is in early-stage clinical trials; failure to demonstrate safety and efficacy in later phases could halt development.
• Regulatory Risk: Obtaining FDA approvals for PAS-004 in multiple indications involves complex regulatory processes with uncertain outcomes.
• Financial Risk: The company reports net losses and relies on external financing; inability to secure funding could impair operations.
• Competitive Risk: Existing FDA-approved MEK inhibitors and other emerging therapies may limit market opportunity for PAS-004.
• Operational Risk: Execution risks include successful completion of clinical trials, manufacturing scale-up, and regulatory submissions.
Business trends: Advancement of PAS-004 clinical trials in NF1 and advanced cancers, expansion into additional indications including ALS and inflammatory diseases, supported by regulatory designations and funding.
Execution milestones: Completion of Phase 1/1b NF1 trial Part A, regulatory-required ADME and toxicology studies, dose escalation in advanced cancer trial, and formulation development.
Key risks: Clinical and regulatory uncertainties for PAS-004, financial dependence on external funding, competitive pressures from existing MEK inhibitors, and operational execution challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on discovery, research, and development of treatments for RASopathies, MAPK pathway-driven tumors, and CNS disorders [S1].
- The lead product candidate is PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor designed to improve selectivity, oral bioavailability, and metabolic stability compared to existing MEK inhibitors [S1].
- PAS-004 targets diseases including neurofibromatosis type 1 (NF1), MAPK pathway-driven tumors (e.g., BRAFv600 mutations), amyotrophic lateral sclerosis (ALS), and inflammatory diseases such as inflammatory bowel disease (IBD) and ankylosing spondylitis [S1].
- PAS-004 has received FDA orphan drug designation for ALS and NF1, and FDA rare pediatric disease status for NF1-PN [N1][N3][S1].
- The company is conducting a first-in-human Phase 1 multicenter open-label trial of PAS-004 in patients with MAPK pathway-driven advanced tumors, with dose escalation ongoing and no maximum tolerated dose reached as of the latest update [S1].
- PAS-004 has demonstrated a favorable safety profile with only Grade 1 and 2 treatment-related adverse events, no dose interruptions, and a long half-life (~60 hours) with stable pharmacokinetics [S1].
- A Phase 1/1b clinical trial for PAS-004 in adult patients with symptomatic, inoperable NF1-PNs is underway at multiple sites in the US, Australia, and South Korea, with Part A dose escalation expected to complete by end of 2026 [S1].
- The company plans to complete key regulatory-required studies including ADME, toxicology, drug-drug interaction, and food effect studies in 2026-2028 to support registrational trials [S1].
- PAS-004 is administered orally in capsule and tablet formulations, with tablet formulation intended for commercial use; additional formulations such as liquid and topical are under evaluation [S1].
- The company has a second discovery program PAS-001 targeting complement component 4A for schizophrenia, currently in early development [S1].
- Pasithea reported a net loss of $6.58 million and basic and diluted EPS of -$0.20 for the quarter ended September 30, 2026 [S2].
- As of September 30, 2026, Pasithea had $41.2 million in cash and equivalents, current assets of $43.2 million, current liabilities of $2.76 million, resulting in a current ratio of 15.67 and cash ratio of 14.96, indicating strong liquidity [S2].
- Recent corporate developments include appointment of Kartik Krishnan as Chief Medical Officer and Dr. James Lee to the Scientific Advisory Board to advance PAS-004 development [N2][N6].
- The company completed a $60 million equity offering in late 2025 to advance PAS-004 and its broader pipeline [N5].
- Interim clinical data showed tumor shrinkage in neurofibromatosis trials and promising Phase 1 results demonstrating up to 91% pERK inhibition and tumor volume reduction in advanced cancer patients [N7][N1].
- The ALS Association awarded $1 million to support an investigator-initiated trial of PAS-004 in ALS [S1].
- HC Wainwright & Co. initiated coverage of Pasithea Therapeutics with a buy recommendation in December 2025 [N4].
Generated 2026-11-14
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-06-02 | www.nasdaq.com | Pasithea Therapeutics' PAS-004 Receives FDA Orphan Drug Designation For ALS | https://www.nasdaq.com/articles/pasithea-therapeutics-pas-004-receives-fda-orphan-drug-designation-als
- N2 | 2026-05-04 | www.nasdaq.com | Pasithea Therapeutics Appoints Kartik Krishnan As CMO | https://www.nasdaq.com/articles/pasithea-therapeutics-appoints-kartik-krishnan-cmo
- N3 | 2026-04-20 | www.nasdaq.com | Pasithea Wins FDA Rare Pediatric Disease Status For PAS-004 To Treat Neurofibromatosis Type 1 | https://www.nasdaq.com/articles/pasithea-wins-fda-rare-pediatric-disease-status-pas-004-treat-neurofibromatosis-type-1
- N4 | 2025-12-08 | www.nasdaq.com | HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-initiates-coverage-pasithea-therapeutics-ktta-buy-recommendation
- N5 | 2025-12-01 | www.nasdaq.com | Pasithea Prices $60 Mln Offering To Advance PAS-004 And Broader Pipeline | https://www.nasdaq.com/articles/pasithea-prices-60-mln-offering-advance-pas-004-and-broader-pipeline
- N6 | 2025-06-11 | www.nasdaq.com | Pasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory Diseases | https://www.nasdaq.com/articles/pasithea-therapeutics-appoints-dr-james-lee-scientific-advisory-board-advance-pas-004
- N7 | 2025-06-02 | www.nasdaq.com | Pasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025 | https://www.nasdaq.com/articles/pasithea-therapeutics-reports-promising-interim-results-pas-004-phase-1-trial-refractory
- N8 | 2025-05-20 | www.nasdaq.com | Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model | https://www.nasdaq.com/articles/pasithea-announces-strong-preclinical-results-pas-004-inflammatory-disease-model
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


